10.1093/jxb/erq358 10 EspunyaM
doi:10.1080/15287399409531852
But spend five minutes on Reddit and youd think its half the crowd
The standard dosing schedule is: Weeks 14 : 0.25 mg once weekly (initial dose) Weeks 58 : 0.5 mg once weekly Weeks 912 : 1 mg once weekly Weeks 1316 : 1.7 mg once weekly Week 17 and onward : 2.4 mg once weekly (maintenance dose for adults and pediatric patients aged 12 years and older) This gradual increase reduces the risk of side effects like nausea and ensures the body adapts to the medication
And that has to do with the short chain fatty acids being good for the gut, and a lot of work done by a former colleague of mine and good friend, Mark Shigenaga, showing that the short chain citrate, malate, lactate, but specifically malate, really, and lactate are the major ones that get into the gut epithelial cells and are an energy source for the mitochondria and the goblet cells
How GLP-1 Receptor Agonists and SGLT2 Inhibitors Work Together Benefits of Combining GLP-1 and SGLT2 Inhibitor Treatment Who Is Suitable for GLP-1 and SGLT2 Inhibitor Combination Therapy